Dear Members of the Englander Institute,
Thank you all so much for a very successful and productive October!
Please join me in congratulating (from left) our Scientific Director Dr. MassimoCristofanilli, our Director of Bladder Cancer Research Dr. Bishoy Faltas, and colleagueDr. Lorenzo Galluzzi for earning major new grants last month (see details below). 
Excitement is building for this week's 2023 International Cancer Genomics Consortium Scientific Workshop, hosted by the EIPM! The Workshop will truly be a global cancer genomics initiative, with almost all continents involved in creating a clinically focused database of cancer genomes to support clinical care and research.
The November 7-9 Workshop will explore two strong themes - diversity of genomic data and overcoming obstacles to sharing data/building large cohorts. We anticipate that 175-250 guests will join the 3 day event, including the heads of several national cancer genome projects. Please note the Workshop is a closed meeting. Registration is required.
I hope you enjoy reading about our October accomplishments, including new awards, media coverage of our work, upcoming meetings, and impressive publications by a range of EIPM colleagues.
Thank you again for your continued hard work and dedication to our mission.
Sincerely,
Olivier Elemento, Ph.D.
News Coverage & Awards 
Congratulations to Dr. Lorenzo Galluzzi on earning a $3.5M grant on October 10th from the National Cancer Institute for a study entitled “Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer.”
Our Scientific Director Dr. Massimo Cristofanilli was awarded a $2.3M U.S. Department of Defense Breast Cancer Research Program Breakthrough Award for his project “Early Detection Blood Test for Universal Breast Cancer Screening to Improve Early Diagnosis for Women of All Social and Ethnic Backgrounds.” Additionally, Dr. Cristofanilli was interviewed by Spectrum News on October 25th regarding his work with liquid biopsy to detect and treat breast cancer as early as possible.
A $610,000 grant from the U.S. Department of Defense was awarded to researchers at the EIPM and the Meyer Cancer Center led by our Director of Bladder Cancer Research Dr. Bishoy Faltas to study the mechanisms that drive the spread of bladder cancer. Additionally, Dr. Bishoy Faltas guest edited the Urologic Oncology Special Issue on advances in UC treatments on October 11th. 
Congratulations to our colleague Dr. Lisa Newman, chief of the section of breast surgery, and Dr. Jedd Wolchok, Director of the Meyer Cancer Center, on their October 9th election into the National Academy of Medicine. Dr. Newman made Breast Cancer Awareness Month news for her work promoting the Shoes for a Cure charity shoe sale, which raised $600,000 for breast cancer research. Dr. Newman was also interviewed for the News 12 broadcast segment "Turn To Tara team investigates racial disparities in breast cancer outcomes," on October 25th. 
The Urology Times covered new mCRPC research, "Radio–antibody drug conjugate elicits antitumor activity in PSMA-positive mCRPC," by Dr. Scott T. Tagawa on October 19th. 
I was interviewed for the article "AI in Oncology: Current and Future Applications," which appeared in Dermatology Advisor on October 20th. A similar article ran in Oncology Nurse Advisor on October 31st.
Events
Clinical Director Dr. Cora N. Sternberg delivered a presentation on "Precision Medicine in Prostate Cancer" at the annual Italian Society of Urology (SIU) conference in Rome on October 9th.
I was happy to present "From Cancer Models to Digital Avatars - Building Virtual Models of Cancer," at the Virtual Human Global Summit 2023 on October 4th at the Brookhaven Lab. 
Our Director for Liquid Biopsy Research Dr. Pashtoon Kasi participated in the Endpoints Webinar "Re-activating the immune system against cancer: The next I-O revolution," on October 18th. 
Dr. Pinkal Desai presented at the 2023 Lymphoma, Leukemia & Myeloma Congress. The title of her talk was "All Non-FLT3 Mutated AML Patients Above Age 60 with ELN Intermediate or Adverse Risk Should Be Treated with Azacitidine and Venetoclax--Yes."
Publications
Dr. Roberto De Gregorio and colleagues published "miR-218 promotes dopaminergic differentiation and controls neuron excitability and neurotransmitter release through the regulation of a synaptic-related genes network," in The Journal of Neuroscience on October 10th. 
Our Clinical Director Dr. Cora Sternberg and colleagues published "Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial," in The Oncologist on October 9th. 
Drs. Massimo Cristofanilli and Eleni Andreopoulou published "Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications," in The Journal of Liquid Biopsy on October 8th. 
Dr. Yajas Shah, myself, and colleagues published "Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence," in Clinical Cancer Research on October 13th. 
Dr. Lorenzo Galluzzi's latest review article "Immunosurveillance in clinical cancer management," was published in CA: A Cancer Journal for Clinicians on October 25th. Dr. Galluzzi also published "Mitochondrial control of antigen presentation in cancer cells," in Cancer Cellon October 26th. 
I was pleased to publish the Journal Article "The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review," in The Oncologiston October 25th.